Published in Communications Biology · View the paper (DOI)
Researchers at Goethe University Frankfurt and University of Kent have discovered that the enzyme SAMHD1 can split phosphate groups off nelarabine, making it less effective in B-ALL patients. This breakthrough could lead to more targeted treatment options for individual patients.
Coverage from 2 institutions